Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis
Clicks: 513
ID: 113002
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
81.0
/100
513 views
351 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #3 of 41 articles by views in annals of the rheumatic diseases
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Discontinuation of bDMARDs leads to an increased risk of losing remission or LDA and radiographic progression, while tapering doses of bDMARDs does not increase the risk of relapse (LDA) or radiographic progression, even though there is an increased risk of losing remission.
| Reference Key |
s2018annalsrisk
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Henaux S;Ruyssen-Witrand A;Cantagrel A;Barnetche T;Fautrel B;Filippi N;Lukas C;Raffeiner B;Rossini M;Degboé Y;Constantin A;; |
| Journal | annals of the rheumatic diseases |
| Year | 2018 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
systematic review
meta-analysis
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
treatment outcome
female
male
Withholding Treatment*
risk factors
radiography
antirheumatic agents / therapeutic use*
arthritis
rheumatoid / drug therapy*
disease progression
pmid:29187350
doi:10.1136/annrheumdis-2017-212423
sophie henaux
adeline ruyssen-witrand
arnaud constantin
rheumatoid / diagnostic imaging
biological products / therapeutic use*
maintenance chemotherapy
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.